Ligand binding sensitivity of the extracellular loop two of the cannabinoid receptor 1

Drug Development Research

Volumn 71, Issue 7, 2010, Pages 404-411

  Bertalovitz, Alexander C ^a   Ahn, Kwang H ^a   Kendall, Debra A ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

cannabinoid receptor 1; extracellular loop 2; G protein coupled receptor; ligand binding

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (1 METHANESULFONYLAMINO 4 HEXYN 6 YL) 6A,7,10,10A TETRAHYDRO 6,6,9 TRIMETHYL 6H DIBENZO[B,D]PYRAN; 3 (1',1' DIMETHYLETHYL) DELTA8 TETRAHYDROCANNABINOL; 3 (1',1' DIMETHYLPENTYL) DELTA8 TETRAHYDROCANNABINOL; 3 [2 CYANO 3 (TRIFLUOROMETHYL)PHENOXY]PHENYL 4,4,4 TRIFLUORO 1 BUTANESULFONATE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; BAY 593074; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; DEXANABINOL; DRINABANT; IBIPINABANT; JWH 061; JWH 179; METHANANDAMIDE; N (N PIPERIDYL) 3 (2,4 DICHLOROPHENYL) 4 [4' (1' MEHTYLPENTYL)PHENYL] 5 METHYLPYRAZOLE; N (PIPERIDIN 1 YL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 5 (4 PENTYLPHENYL) 1H PYRAZOLE 3 CARBOXAMIDE; N PENTYLPHENYL 5 (4 CHLOROPHENYL) 3 N (PIPERIDIN 1 YL)CARBOXAMIDE 4 METHYLPYRAZOLE; N PIPERIDINYL [8 CHLORO 1 (2,4 DICHLOROPHENYL)] 1,4,5,6 XTETRAHYDROBENZO[6,7]CYCLOHEPTA[1,2 C]PYRAZOLE 3 CARBOXAMIDE; NESS 0327; O 1255; O 1302; O 1690; O 2050; RIMONABANT; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; LIGAND BINDING; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

EID: 78649680824     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20388     Document Type: Article

References (36)

1. Abadji V, Lucas-Lenard JM, Chin C, Kendall DA,. 1999. Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs. J Neurochem 72: 2032-2038.
2. Ahn KH, Bertalovitz AC, Mierke DF, Kendall DA,. 2009. Dual role of the second extracellular loop of the cannabinoid receptor 1: ligand binding and receptor localization. Mol Pharmacol 76: 833-842.
3. Bonhaus DW, Chang LK, Kwan J, Martin GR,. 1998. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287: 884-888.
4. Bradford MM,. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
5. Chen C, Okayama H,. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7: 2745-2752.
6. Cheng Y, Prusoff WH,. 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
7. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, et al. 2007. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318: 1258-1265.
8. Chin CN, Lucas-Lenard J, Abadji V, Kendall DA,. 1998. Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem 70: 366-373.
9. Conner M, Hawtin SR, Simms J, Wootten D, Lawson Z, Conner AC, Parslow RA, Wheatley M,. 2007. Systematic analysis of the entire second extracellular loop of the V(1a) vasopressin receptor: key residues, conserved throughout a G-protein-coupled receptor family, identified. J Biol Chem 282: 17405-17412.
10. Devane WA, Dysarz III FA, Johnson MR, Melvin LS, Howlett AC,. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613.
11. Fay JF, Dunham TD, Farrens DL,. 2005. Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. Biochemistry 44: 8757-8769.
12. Glass M, Felder CC,. 1997. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17: 5327-5333.
13. Griffin G, Wray EJ, Rorrer WK, Crocker PJ, Ryan WJ, Saha B, Razdan RK, Martin BR, Abood ME,. 1999. An investigation into the structural determinants of cannabinoid receptor ligand efficacy. Br J Pharmacol 126: 1575-1584.
14. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. 2002. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
15. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR,. 1999. 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7: 2905-2914.
16. Huffman JW, Miller JR, Liddle J, Yu S, Thomas BF, Wiley JL, Martin BR,. 2003. Structure-activity relationships for 1′,1′-dimethylalkyl- Delta8-tetrahydrocannabinols. Bioorg Med Chem 11: 1397-1410.
17. Hurst D, Umejiego U, Lynch D, Seltzman H, Hyatt S, Roche M, McAllister S, Fleischer D, Kapur A, Abood M, et al. 2006. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction. J Med Chem 49: 5969-5987.
18. Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, Song ZH, Nie J, Lewis D, Reggio PH,. 2002. N-(piperidin-1-yl)-5-(4-chlorophenyl) -1-(2,4-dichlorophenyl)-4-methyl-1H-p yrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol 62: 1274-1287.
19. Janero DR, Makriyannis A,. 2009. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs 14: 43-65.
20. Kapur A, Hurst DP, Fleischer D, Whitnell R, Thakur GA, Makriyannis A, Reggio PH, Abood ME,. 2007. Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol 71: 1512-1524.
21. Lauckner JE, Hille B, Mackie K,. 2005. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci USA 102: 19144-19149.
22. Lim HD, Jongejan A, Bakker RA, Haaksma E, de Esch IJ, Leurs R,. 2008. Phenylalanine 169 in the second extracellular loop of the human histamine H4 receptor is responsible for the difference in agonist binding between human and mouse H4 receptors. J Pharmacol Exp Ther 327: 88-96.
23. Mackie K, Hille B,. 1992. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 89: 3825-3829.
24. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI,. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
25. 1 receptor constitutes an agonist/inverse agonist binding region. J Med Chem 46: 5139-5152.
26. Munro S, Thomas KL, Abu-Shaar M,. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
27. Overington JP, Al-Lazikani B, Hopkins AL,. 2006. How many drug targets are there? Nat Rev Drug Discov 5: 993-996.
28. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. 2000. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289: 739-745.
29. Pertwee RG,. 2009. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397-411.
30. Reggio PH,. 2003. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors. Curr Pharm Des 9: 1607-1633.
31. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, et al. 2007. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318: 1266-1273.
32. Salo OM, Lahtela-Kakkonen M, Gynther J, Jarvinen T, Poso A,. 2004. Development of a 3D model for the human cannabinoid CB1 receptor. J Med Chem 47: 3048-3057.
33. Song ZH, Bonner TI,. 1996. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 49: 891-896.
34. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH,. 1998. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 285: 285-292.
35. Unal H, Jagannathan R, Bhat MB, Karnik SS,. 2010. Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor. J Biol Chem 285: 16341-16350.
36. 1 receptor recognition and activation. J Pharmacol Exp Ther 296: 1013-1022.